| Translated title of the contribution | Cost-effectiveness analysis of Osimertinib in patients with non-CNS, EGFR exon 19 Del mutated metastatic NSCLC in Taiwan |
|---|---|
| Original language | Chinese (Traditional) |
| Supervisors/Advisors |
|
| State | Published - 2021 |
| Externally published | Yes |
以Osimertinib治療臺灣EGFR Exon19 Del且無腦轉移之轉移性非小細胞肺癌患者的成本效益分析
鍾宜庭
Research output: Types of Thesis › Master's thesis